Abstract
The first-generation 5-HT3 receptor antagonists (dolasetron, granisetron, ondansetron, tropisetron, ramosetron, and azasetron) have significant and similar efficacy in the prevention of acute CINV for patients receiving moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC). These agents do not appear to have significant efficacy in the prevention of delayed CINV, and these agents compete primarily on an economic basis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Navari, R.M. (2016). Conclusions. In: Navari, R. (eds) Management of Chemotherapy-Induced Nausea and Vomiting. Adis, Cham. https://doi.org/10.1007/978-3-319-27016-6_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-27016-6_11
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-27014-2
Online ISBN: 978-3-319-27016-6
eBook Packages: MedicineMedicine (R0)